Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTX-102 in Angelman Syndrome
NCT07157254Phase 2Terminated
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 8
01
Overview
A Phase 2 trial of apazunersen in Angelman syndrome (AS), sponsored by Ultragenyx Pharmaceutical Inc.. Started Oct 2025; status: terminated.
02
Drugs
apazunersen
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NCT07157254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07157254.